Table 3.

Tumor heterogeneity.

	Block 1	Block 2	Block 3	Combineda
Cytoplasmic BUB3
n	210	210	196	213
Negative	182	182	138	137
Heterogeneous	NA	NA	NA	63
Positive	28	28	58	13
p valueb	0.089	<0.001	0.001	<0.001
HR (95% CI)	1.71 (0.91–3.21)	3.12 (1.83–5.30)	2.29 (1.41–3.73)	2.12 (1.28–3.50) 4.46 (2.14–9.29)
Nuclear BUB3
n	210	210	196	213
Positive	157	141	139	96
Heterogeneous	NA	NA	NA	103
Reduced	53	69	57	14
p valueb	0.518	0.018	0.152	0.024
HR (95% CI)	1.20 (0.70–2.06)	1.71 (1.09–2.68)	1.44 (0.87–2.40)	1.38 (0.84–2.28) 2.91 (1.31–6.46)
CCNB1
n	221	207	214	223
Negative	152	157	173	136
Heterogeneous	NA	NA	NA	62
Positive	69	50	41	25
p valueb	<0.001	0.001	<0.001	<0.001
HR (95% CI)	2.94 (1.86–4.63)	2.33 (1.42–3.82)	2.51 (1.51–4.19)	2.67 (1.62–4.40) 3.82 (1.99–7.31)
PTTG1
n	214	201	209	221
Negative	149	152	167	124
Heterogeneous	NA	NA	NA	77
Positive	65	49	42	20
p valueb	0.036	0.041	0.014	0.012
HR (95% CI)	1.65 (1.03–2.64)	1.68 (1.04–2.73)	1.95 (1.14–3.34)	1.55 (0.95–2.52) 2.69 (1.33–5.44)

CI confidence interval, HR hazard ratio, NA not available

^aPatients were included in the combined analyses when a patient had ≥2 valid samples, a tumor was considered heterogeneous when both positive and negative scores were observed

^bLog-rank p value